Mark Chandler, MD
Psychiatry · Durham, NCNPI 1265452270
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.6% of the total across 1,050 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 40 manufacturers, the largest accounting for just 14.4% — the pattern of someone who eats at a lot of different presentations. Among psychiatry clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,050 payments — averaging $17.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sunovion Pharmaceuticals Inc.$3K
- Alkermes, Inc.$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- Teva Pharmaceuticals USA, Inc.$1K
- Otsuka America Pharmaceutical, Inc.$1K
- Vanda Pharmaceuticals Inc.$1K
- plus $8K from 34 others
Across 21 payments — averaging $3327.39 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Otsuka Pharmaceutical Development & Commercialization, Inc.$68K
- Shire North American Group Inc$2K
What the payments were for
- Consulting fees$5503%
- Food & beverage$17,24395%
- Education$4322%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Adzenys XR-ODT$671
- Cotempla XR-ODT$671
- Equetro$100
How this compares
$18,225 in reported general payments places this provider in the 95th percentile of 1,108 psychiatry providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LybalviOlanzapine/Samidorphan Malate | 201 | $326,735 |
| RexultiBrexpiprazole | 89 | $141,639 |
| VraylarCariprazine Hcl | 82 | $109,040 |
| IngrezzaValbenazine Tosylate | 14 | $98,438 |
| Invega SustennaPaliperidone Palmitate | 33 | $97,913 |
| FanaptIloperidone | 33 | $85,664 |
| CaplytaLumateperone Tosylate | 35 | $61,542 |
| AristadaAripiprazole Lauroxil | 14 | $44,267 |
| NuedextaDextromethorphan Hbr/Quinidine | 20 | $32,156 |
| Aripiprazole | 567 | $31,538 |
| Lurasidone Hcl | 155 | $30,849 |
| QelbreeViloxazine Hcl | 39 | $28,500 |
| TrintellixVortioxetine Hydrobromide | 44 | $27,599 |
| Fluvoxamine Maleate | 286 | $20,918 |
| BelsomraSuvorexant | 36 | $16,556 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Alkermes, Inc.Lybalvi, Aristada | $2,218 | $371,003215 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,352 | $141,63989 claims |
| Johnson & JohnsonInvega Sustenna, Concerta | $1,115 | $109,73062 claims |
| AbbVieVraylar | $860 | $109,04082 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $657 | $98,43814 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $1,223 | $85,66433 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,590 | $61,54235 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $846 | $34,76863 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $76 | $32,15620 claims |
| Supernus Pharmaceuticals, Inc.Qelbree | $420 | $28,50039 claims |
| Lilly USA, LLCCymbalta, Olanzapine | $63 | $22,546513 claims |
| MerckBelsomra | $44 | $16,55636 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,108 psychiatry providers in North Carolina.
Other psychiatry in Durham
- Mark ReynoldsDurham$3.2M
- Steven SzaboDurham$360K
- Andrew KrystalDurham$234K
- Ranjan SudanDurham$81K
- Caleb WhitenackDurham$68K
- Paolo MannelliDurham$38K
- P DoraiswamyDurham$35K
- David JarrettDurham$28K
- Steven PrakkenDurham$22K
- Mustafa HusainDurham$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.